Despite the wide range of treatment options available, metastatic non-small-cell lung cancer (NSCLC) remains a major cause of cancer-related death. For patients with metastatic (EGFR– and ALK-negative/unknown) NSCLC, chemotherapy is still a mainstay of treatment. However, immune checkpoint inhibitors (Opdivo, Keytruda, and most recently Tecentriq) are revolutionizing the treatment algorithm for this subpopulation. As this market segment continues to evolve at a rapid pace, drug manufacturers must understand the unmet needs associated with the treatment of metastatic NSCLC to identify the opportunities for drug development. We focus on this commercially important subpopulation and assess how current therapies perform on key drug attributes and how these attributes affect medical oncologists’ prescribing decisions. We identify potential hidden opportunities and which emerging therapies (if any) could capitalize upon them. Furthermore, we use conjoint analysis to determine attribute and price trade-offs that surveyed medical oncologists are willing to make when considering treatment options for metastatic NSCLC and simulate the share of preference and likelihood to prescribe of different target product profiles.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in December 2016.
Key companies: Bristol-Myers Squibb, Merck & Co., Eli Lilly & Co., Roche/Genentech
Key drugs: Opdivo, Keytruda, Alimta, Avastin